新辅助化疗在肌层浸润性膀胱癌中的应用现状及研究进展  

Application and research progress of neoadjuvant chemotherapy in muscle-invasive bladder cancer

作　　者：曾世平 黄应龙[1] 李宁[1] 左毅刚(审校)[1] ZENG Shiping;HUANG Yinglong;LI Ning;ZUO Yigang(Department of Urology,Second Affiliated Hospital of Kunming Medical University,Kunming,650000,China)

机构地区：[1]昆明医科大学第二附属医院泌尿外科,昆明650000

出　　处：《临床泌尿外科杂志》2020年第5期413-416,420,共5页Journal of Clinical Urology

基　　金：国家自然科学基金(No:81660423);云南省基础研究计划[No:2018FE001(-238)];云南省医疗卫生单位内设机构研究项目(No:2018NS0301)。

摘　　要：膀胱癌在泌尿系恶性肿瘤中具有极高的发病率,其中肌层浸润性膀胱癌恶性程度高,容易发生淋巴结及远处转移,预后差,其治疗以根治性膀胱切除+盆腔淋巴结清扫术为主。术前辅以化疗,能够提高患者术后生存率,增加患者的受益,目前处于肌层浸润性膀胱癌围手术期治疗研究的热点,本文结合中外多中心的研究结果,分析了肌层浸润性膀胱癌新辅助化疗的应用价值、方案选择及研究进展。Bladder cancer has a very high morbidity in urinary malignancies.Among them,muscle-invasive bladder cancer has a high degree of malignancy,and is prone to lymphnode and distant metastasis.The prognosis is poor,and the treatment mainly consists of radical cystectomy and pelvic lymphnode dissection.Preoperative adjuvant chemotherapy can improve the survival rate of patients after surgery and increase the benefits of patients.Currently,neoadjuvant chemotherapy for muscle-invasive bladder cancer is a hot spot in the perioperative treatment research.In this paper,the application value,program selection and research progress of neoadjuvant chemotherapy for muscle-invasive bladder cancer were analyzed based on the results of multiple centers at home and abroad.

关 键 词：膀胱癌 肌层浸润性膀胱癌 新辅助化疗 分子生物学 

分 类 号：R737.14[医药卫生—肿瘤]